INBX Latest Headlines

INBX Highlights: Ozekibart Shows Robust Disease Control Rate of 87% in Late-Line Colorectal Cancer—Durable Responses Outpace Historical Norms

Market Chameleon (Wed, 22-Apr 10:28 AM)

INBX’s Ozekibart Delivers 20% Response Rate and 87% Disease Control in Late-Line Colorectal Cancer—Durable Results in Tough-to-Treat Patients

Market Chameleon (Wed, 22-Apr 7:34 AM)

GE Vernova, Boston Scientific, Intuitive Surgical And Other Big Stocks Moving Higher On Wednesday

at www.benzinga.com (Wed, 22-Apr 9:56 AM)

Dow Jumps Over 400 Points; Boeing Posts Upbeat Q1 Results

at www.benzinga.com (Wed, 22-Apr 9:41 AM)

Inhibrx cancer drug reportedly drawing interest of Merck and rivals

at seekingalpha.com (Wed, 22-Apr 8:37 AM)

Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)

at www.tipranks.com (Wed, 22-Apr 7:27 AM)

Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data

at www.tipranks.com (Tue, 21-Apr 4:49 PM)

Inhibrx Cuts R&D Costs Sharply as Two Clinical Trials Push Toward Key 2026 Milestones

Market Chameleon (Fri, 20-Mar 10:59 AM)